Menu
1 min read · estimated
APPROVED USE
What FDA approved
Interchangeable Prolia biosimilar whose oncology-related uses increase bone mass in men at high fracture risk on androgen deprivation for nonmetastatic prostate cancer and women at high fracture risk on adjuvant aromatase inhibitor therapy for breast cancer.
LAMPGEN ANALYSIS
Why it matters
This presentation addresses treatment-associated bone loss in the specified patients, distinct from the Wyost indications.
What research teams should watch
Verify fracture risk, calcium and the oncology regimen, and keep the six-month dosing schedule separate from oncology-dose denosumab orders.
PRIMARY RECORDS